Lincoln Pharmaceuticals (BOM:531633) YoY EBITDA Growth : -21.86% (As of Mar. 2025)

View and export this data going back to 2000. Start your Free Trial

What is Lincoln Pharmaceuticals YoY EBITDA Growth?

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months. Lincoln Pharmaceuticals's YoY EBITDA Growth for the quarter that ended in Mar. 2025 was -21.86%.

Lincoln Pharmaceuticals's EBITDA per Share for the three months ended in Mar. 2025 was ₹9.91.

Lincoln Pharmaceuticals YoY EBITDA Growth Historical Data

The historical data trend for Lincoln Pharmaceuticals's YoY EBITDA Growth can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Lincoln Pharmaceuticals YoY EBITDA Growth Chart

Lincoln Pharmaceuticals Annual Data

Trend

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

Mar24

Mar25

YoY EBITDA Growth

Get a 7-Day Free Trial

21.42

13.48

6.04

20.70

-7.71

Lincoln Pharmaceuticals Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
YoY EBITDA Growth	Get a 7-Day Free Trial															25.99	16.70	-3.72	-19.77	-21.86

Lincoln Pharmaceuticals YoY EBITDA Growth Calculation

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months.

Lincoln Pharmaceuticals's YoY EBITDA Growth for the fiscal year that ended in Mar. 2025 is calculated as:

	YoY EBITDA Growth (A: Mar. 2025 )
=	(EBITDA per Share (A: Mar. 2025 )	-	EBITDA per Share (A: Mar. 2024 ))	/	\| EBITDA per Share (A: Mar. 2024 ) \|
=	(61.889	-	67.062)	/	\| 67.062 \|
=	-7.71 %

Lincoln Pharmaceuticals's YoY EBITDA Growth for the quarter that ended in Mar. 2025 is calculated as:

	YoY EBITDA Growth (Q: Mar. 2025 )
=	(EBITDA per Share (Q: Mar. 2025 )	-	EBITDA per Share (Q: Mar. 2024 ))	/	\| EBITDA per Share (Q: Mar. 2024 )) \|
=	(9.906	-	12.677)	/	\| 12.677 \|
=	-21.86 %

Lincoln Pharmaceuticals YoY EBITDA Growth Related Terms

Thank you for viewing the detailed overview of Lincoln Pharmaceuticals's YoY EBITDA Growth provided by GuruFocus.com. Please click on the following links to see related term pages.

Lincoln Pharmaceuticals Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Lincoln Pharmaceuticals Ltd (BOM:531633) » Definitions » YoY EBITDA Growth

Traded in Other Exchanges

LINCOLN:India

Address

Science City Road, Lincoln House, Behind Satyam Complex, Sola, Ahmedabad, GJ, IND, 380060

Website

https://www.lincolnpharma.com

Lincoln Pharmaceuticals Ltd is an India-based company engaged in the business of manufacturing and trading of pharmaceutical products. It offers products in the fields of cardiac, diabetic, anti-malarial, anti-biotic, anti-fungal, cephalosporin, analgesics, anesthetics, anti-pyretic, GIT products, vitamin-minerals, and iron preparations. Some of the key brands through which the company markets its products are; Rhino, Binafin, Kezolin, Hepalin, Progut, and Vomistat among others. Geographically, it carries out sales in India and outside India; generating key revenue from outside India.

Lincoln Pharmaceuticals Headlines

No Headlines